B
TEVA icon

BP’s Teva Pharmaceuticals TEVA Stock Holding History

BP’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,529
Closed -$292K – 474
2021
Q2 		$292K Sell
29,529
-15,363
-34% -$163K 0.01% 546
2021
Q1 		$518K Hold
44,892
– – 0.02% 463
2020
Q4 		$433K Buy
+44,892
New +$430K 0.01% 515

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BP's TEVA Position: Q3 2021 in Review

BP sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 29,529 shares — an estimated $292K sold.

BP first reported a position in TEVA in Q4 2020 and held it in 3 quarters. The position peaked at $518K in Q1 2021. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • BP reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BP sold 29,529 Teva Pharmaceuticals shares in Q3 2021, an estimated $292K.
  • BP first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • BP's Teva Pharmaceuticals position peaked at $518K in Q1 2021.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.